# Study of Curcumin, Vorinostat, and Sorafenib

> **NCT01608139** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Curcumin
- **DRUG:** Sorafenib
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT01608139
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-11
- **Primary completion:** 2022-11
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01608139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01608139, "Study of Curcumin, Vorinostat, and Sorafenib". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01608139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*